Analysts think CYCC stock price could increase by 572%
Jun 14, 2024, 6:27 AM
16.17%
What does CYCC do
Cyclacel Pharmaceuticals Inc., based in Berkeley Heights, New Jersey, is a clinical-stage biopharmaceutical company focused on developing cancer therapies using cell cycle and mitosis control biology. The company's key projects include fadraciclib, a CDK9 inhibitor for tumors, and plogosertib, a PLK1 inhibitor showing efficacy in tumor models.
4 analysts think CYCC stock price will increase by 571.86%. The current median analyst target is $11.22 compared to a current stock price of $1.67. The lowest analysts target is $11.11 and the highest analyst target is $11.55.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.